Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

CYP2C9 gene variants, drug dose, and bleeding risk in warfarin-treated patients: a HuGEnet systematic review and meta-analysis.

Genetics in medicine : official journal of the American College of Medical Genetics - 1 Feb 2005

Sanderson Simon, Emery Jon, Higgins Julian

Abstract excerpt

PURPOSE: Two common variant alleles of the cytochrome CYP2C9 (CYP2C9*2 and CYP2C9*3) lead to reduced warfarin metabolism in vitro and in vivo. The study objective was to examine the strength and quality of existing evidence about CYP2C9 gene variants and clinical outcomes in warfarin-treated patients. METHODS: The study was a systematic review and meta-analysis. Multiple electronic databases were searched,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anticoagulants
Share to Aryl Hydrocarbon Hydroxylases

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Cytochrome P-450 CYP2C9

Share to Databases, Factual

Share to Hemorrhage

Share to Pharmacogenetics

Share to Treatment Outcome

Share to Warfarin

Source

Identifiers

PMID: 15714076
DOI: 10.1097/01.gim.0000153664.65759.cf

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

CYP2C9 gene variants, drug dose, and bleeding risk in warfarin-treated patients: a HuGEnet systematic review and meta-analysis.PMID 15714076Read ↗

Influence of CYP2C9 genotype on warfarin dose requirements--a systematic review and meta-analysis.Semantic proximity Read ↗

Cytochrome P450 polymorphisms are associated with reduced warfarin dose.Semantic proximity Read ↗

Genetic polymorphism of the human cytochrome P450 2C9 gene and its clinical significance.Semantic proximity Read ↗

Cytochrome P450 2C9 polymorphisms: a comprehensive review of the in-vitro and human data.Semantic proximity Read ↗

Pharmacogenomics of CYP2C9: Functional and Clinical ConsiderationsSemantic proximity Read ↗

First report of warfarin dose requirements in patients possessing the CYP2C9*12 allele.Semantic proximity Read ↗

Frequency of CYP2C9 polymorphisms affecting warfarin metabolism in a large anticoagulant clinic cohort.Semantic proximity Read ↗

Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C9 and VKORC1 genotypes and warfarin dosing.Semantic proximity Read ↗

Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications.Semantic proximity Read ↗

Warfarin dose and the pharmacogenomics of CYP2C9 and VKORC1 - rationale and perspectives.Semantic proximity Read ↗

Influence of CYP2C9 and VKORC1 on patient response to warfarin: a systematic review and meta-analysis.Semantic proximity Read ↗

Genotype and risk of major bleeding during warfarin treatment.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.